SCHEMBL27218014

SCHEMBL27218014

CC(C)(c1cc(NC(=O)Nc2ccc(Br)n3ccnc23)no1)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.46
▸ HTT P42858 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ RAB9A P51151 4/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ BRAF P15056 3/20 0.45
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ MAPK14 Q16539 7/20 0.42
▸ MAPK13 O15264 1/20 0.41
▸ RAF1 P04049 4/20 0.40
▸ CSF1R P07333 2/20 0.40
▸ RET P07949 2/20 0.40
▸ PDGFRB P09619 2/20 0.40
▸ KIT P10721 2/20 0.40
▸ FLT3 P36888 2/20 0.40
▸ RIPK2 O43353 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27217995 0.90 MAPT (0.57) MAPTHTTPOLBKDM4ERAB9A
SCHEMBL27217842 0.83 NEK7 (0.48) BRAFMAPK14MAPK13RAF1RET
SCHEMBL27217783 0.81 NEK7 (0.49) MAPTHTTPOLBKDM4EBRAF
SCHEMBL27217793 0.81 SMN1; SMN2 (0.39) MAPTHTTPOLBKDM4ERAB9A
SCHEMBL27217733 0.80 MAPK14 (0.45) BRAFMAPK14MAPK13RAF1CYP2C19
SCHEMBL27217961 0.78 MAPT (0.36) MAPTHTTPOLBKDM4ERAB9A
SCHEMBL30813395 0.78 NEK7 (0.57) FLT3
SCHEMBL27217760 0.77 NEK7 (0.47) MAPTHTTPOLBKDM4ERAB9A
SCHEMBL27217853 0.77 NEK7 (0.46) MAPTHTTPOLBKDM4ERAB9A
SCHEMBL27217821 0.77 NEK7 (0.36) MAPTHTTPOLBKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158394-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-05-16 — — US disclosed
WO-2024059200-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158394-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 MAPT 72/4885HTT 1937/4885POLB 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback